Final Combo Product Dispute Resolution Guidelines Largely Unchanged
This article was originally published in The Gray Sheet
Executive Summary
FDA's final guidance on formal dispute resolutions for combination products provides additional details on when it is appropriate to file a complaint regarding the review time for a combo product submission
You may also be interested in...
Combo Product Office To Tackle Intercenter Agreements, “Chemical Action”
FDA's final rule defining primary mode of action will be released within the next six months, Office of Combination Products Director Mark Kramer projected Jan. 11-12
Combo Products Typically Would Require Only One User Fee Payment – FDA
FDA is proposing to levy two user fees from a combination product sponsor if separate marketing applications are filed, though one of the fees would be waived under certain circumstances
Combo Product Dispute Resolution, Primary Mode Of Action Detailed By OCP
Combination products without regulatory precedent will be assigned to the FDA center with the most expertise in evaluating the products' primary safety and efficacy concerns, according to a proposed rule published in the May 7 Federal Register